SCHEMBL7048265

SCHEMBL7048265

COc1ccc(COc2cccc(C(=O)Nc3ccccc3S(=O)(=O)NC(C)=O)c2)cc1

nearest known ligand 0.60

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SMPD1 P17405 3/20 0.60
MEN1 O00255 3/20 0.53
KMT2A Q03164 3/20 0.53
SMN1; SMN2 Q16637 3/20 0.49
ALDH1A1 P00352 3/20 0.49
GAA P10253 2/20 0.49
MAPT P10636 2/20 0.49
TSHR P16473 1/20 0.49
TP53 P04637 1/20 0.49
HDAC1 Q13547 2/20 0.49
HDAC3 O15379 1/20 0.49
HDAC2 Q92769 1/20 0.49
NCOR2 Q9Y618 1/20 0.49
ABCB1 P08183 1/20 0.48
RAB9A P51151 3/20 0.48
HDAC8 Q9BY41 1/20 0.48
HDAC6 Q9UBN7 1/20 0.48
KDM4E B2RXH2 2/20 0.47
NR1H4 Q96RI1 2/20 0.47
NPC1 O15118 2/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7045371 0.93 KMT2A (0.62) SMPD1MEN1KMT2ASMN1; SMN2ALDH1A1
SCHEMBL7049781 0.90 SMPD1 (0.61) SMPD1MEN1KMT2ASMN1; SMN2ALDH1A1
SCHEMBL7048385 0.90 MAOA (0.57) SMPD1MEN1KMT2AALDH1A1GAA
SCHEMBL7048541 0.89 NR4A1 (0.57) SMPD1MEN1KMT2ASMN1; SMN2ALDH1A1
SCHEMBL7047622 0.88 MAOB (0.60) SMPD1MEN1KMT2AALDH1A1GAA
SCHEMBL7047746 0.87 SMPD1 (0.64) SMPD1MEN1KMT2ASMN1; SMN2ALDH1A1
SCHEMBL7049348 0.87 MAOB (0.60) MEN1KMT2ASMN1; SMN2ALDH1A1GAA
SCHEMBL7051481 0.86 SMPD1 (0.53) SMPD1MEN1KMT2ASMN1; SMN2ALDH1A1
SCHEMBL7050510 0.86 SMPD1 (0.52) SMPD1MEN1KMT2ASMN1; SMN2ALDH1A1
SCHEMBL7052824 0.86 SMPD1 (0.62) SMPD1MEN1KMT2AALDH1A1GAA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20030191323-A1 Hypoglycemic agent AJINOMOTO CO., INC. (JP) 2003-10-09 US disclosed
US-20030162818-A1 Acylsulfonamide derivative AJINOMOTO CO. INC. (JP) 2003-08-28 US disclosed
US-6555584-B1 Acetyl-coa carboxylase inhibitors AJINOMOTO CO., INC. (JP) 2003-04-29 US disclosed
EP-1300142-A1 HYPOGLYCEMICS Ajinomoto Co., Inc. (JP) 2003-04-09 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030162818-A1 Acylsulfonamide derivative ACSS2, ACACA, FASN SMPD1 760/4885MEN1 4502/4885KMT2A 934/4885
US-20030191323-A1 Hypoglycemic agent GPR119, IAPP, SLC5A2 SMPD1 156/4885MEN1 3302/4885KMT2A 1780/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.